- Veracyte Inc (NASDAQ: VCYT) has commenced an underwritten public offering of $400 million in common stock. Underwriters have an option to purchase up to an additional $60 million shares.
- Veracyte will use proceeds to finance its Decipher Biosciences acquisition announced yesterday and working capital and other general corporate purposes.
- Goldman Sachs and SVB Leerink are acting as joint lead book-running managers for the offering.
- Price Action: VCYT closed 13.47% higher at $73.79 on Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in